Evaluation of Cilostazol in Combination With L-Carnitine (ECLECTIC)

This study has been completed.
Sponsor:
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Colorado Prevention Center
ClinicalTrials.gov Identifier:
NCT00822172
First received: January 13, 2009
Last updated: April 11, 2013
Last verified: April 2013

January 13, 2009
April 11, 2013
September 2008
November 2010   (final data collection date for primary outcome measure)
  • The Effect of Cilostazol Combined With L-carnitine on Change in Peak Walking Time (PWT) Compared to Cilostazol Alone From Baseline/Day 0 to Day 180 in Subjects With Peripheral Artery Disease (PAD) Limited by Intermittent Claudication (IC). [ Time Frame: Day 0 to Day 180 ] [ Designated as safety issue: No ]
  • Safety of Combining Cilostazol With L-carnitine by Evaluating Laboratory Abnormalities and Adverse Events (AEs). [ Time Frame: Day 0 to Day 210 ] [ Designated as safety issue: Yes ]
  • To determine the effect of cilostazol combined with L-carnitine on change in peak walking time (PWT) compared to cilostazol alone from Baseline/Day 0 to Day 180 in subjects with PAD limited by intermittent claudication (IC). [ Time Frame: Day 0 to Day 180 ] [ Designated as safety issue: No ]
  • To assess the safety of combining cilostazol with L-carnitine by evaluating laboratory abnormalities and adverse events (AEs). [ Time Frame: Day 0 to Day 210 ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00822172 on ClinicalTrials.gov Archive Site
  • The Combination of Cilostazol and L-carnitine on PWT Compared to Cilostazol Alone From Baseline/Day 0 to Day 90 in Subjects With Peripheral Artery Disease (PAD) Limited by Intermittent Claudication (IC). [ Time Frame: Day 0 to Day 90 ] [ Designated as safety issue: No ]
  • The Effect of the Combination of Cilostazol and L-carnitine on Claudication Onset Time (COT) and Quality of Life (QOL), as Measured Using the Walking Impairment Questionnaire (WIQ) and SF-36v2® at Days 90 and 180. [ Time Frame: Day 0 to Days 90 and 180 ] [ Designated as safety issue: No ]
  • To evaluate the combination of cilostazol and L-carnitine on PWT compared to cilostazol alone from Baseline/Day 0 to Day 90 in subjects with PAD limited by IC. [ Time Frame: Day 0 to Day 90 ] [ Designated as safety issue: No ]
  • To evaluate the effect of the combination of cilostazol and L-carnitine on claudication onset time (COT) and Quality of Life (QOL), as measured using the Walking Impairment Questionnaire (WIQ) and SF-36v2® at Days 90 and 180. [ Time Frame: Day 0 to Days 90 and 180 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Evaluation of Cilostazol in Combination With L-Carnitine
Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication

The purpose of this study is to see how safe and effective L carnitine taken with cilostazol is compared to placebo taken with cilostazol for people with intermittent claudication. A second purpose of the study is to see if L-carnitine is absorbed into the blood stream.

Peripheral Artery Disease (PAD) is a narrowing of the blood vessels that supply the leg with blood. It is caused by atherosclerosis (hardening of the arteries).

Muscles require oxygen carried by the blood. When the leg muscles do not get enough blood and oxygen, this can cause pain, cramping, fatigue, and/or discomfort in the leg muscles during walking or exercise. These symptoms are called intermittent claudication (IC). In more severe cases, tissues do not get enough blood and oxygen at rest, and pain may also be present when the legs are resting. Peripheral Artery Disease (PAD)is one of the most common causes of pain and disability in people between 55 and 75 years of age.

Cilostazol is a medication currently available by prescription for intermittent claudication. L-carnitine is an over-the-counter supplement. It is a natural substance in the human body and is also in some red meats, nuts, and energy drinks.

Some subjects in the study will take L-carnitine with cilostazol and others will take placebo with cilostazol. The purpose of this study is to see how safe and effective L carnitine taken with cilostazol is compared to placebo taken with cilostazol for people with intermittent claudication. A placebo is a tablet or pill that looks like regular medication, but it doesn't have any actual medicine in it. A second purpose of the study is to see if L-carnitine is absorbed into the blood stream.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Peripheral Vascular Disease
  • Intermittent Claudication
  • Peripheral Arterial Disease
  • Dietary Supplement: Levocarnitine tartrate
    Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.
    Other Names:
    • Carnitine
    • L-carnitine
    • Levocarnitine
  • Drug: cilostazol

    Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.

    Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.

    Other Name: Pletal
  • Active Comparator: Cilostazol + L-Carnitine
    Interventions:
    • Dietary Supplement: Levocarnitine tartrate
    • Drug: cilostazol
  • Placebo Comparator: Cilostazol + Placebo
    Intervention: Drug: cilostazol

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
164
December 2010
November 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The subject is >40 years old.
  • The subject has a diagnosis of Intermittent Claudication (IC) due to Peripheral Artery Disease (PAD).
  • Ankle brachial index (ABI) < 0.90 in at least one extremity, or if Ankle brachial index (ABI)is ≥ 0.90 to ≤ 1.0, a reduction of at least 20% in Ankle brachial index (ABI), in at least one extremity, when measured within 1 minute after claudication-limiting treadmill testing. If the subject has non-compressible arteries then a toe brachial index (TBI) < 0.70 is required in at least one extremity.
  • Symptoms of Intermittent Claudication (IC)must be stable for at least 3 months prior to Screening 1.
  • Peak Walking Time (PWT) of ≥ 1 to ≤ 12 minutes on a Gardner protocol at Screening 2.
  • If the subject is currently on statin therapy, they need to have been on statin therapy for at least 3 months prior to Screening 1. Subjects who have recently discontinued statin therapy must "wash-out" for at least one month prior to Screening 1.
  • Tolerance to background therapy of cilostazol (approximately 2 weeks of 50 mg by mouth (PO) twice daily (BID), approximately 1 week of 100 mg PO BID) between Screening 2 and Baseline Visit.
  • Subjects must be either male or females that are post-menopausal, surgically incapable of bearing children or if they are of childbearing potential must have a negative serum pregnancy test at Screening 1 and a negative urine pregnancy test at Day 0 and must agree to use double-barrier contraceptive methods until the end of investigational therapy (Day 180 Visit).
  • The subject is able to comply with scheduled visits, treatment plan and laboratory tests.
  • The subject is willing to participate in this study as documented by written informed consent.
  • During the tolerance phase of the Screening period, the subject demonstrates at least 70% compliance with cilostazol and is willing to continue treatment.

Exclusion Criteria:

  • Evidence of critical limb ischemia (CLI) (e.g., ischemic rest pain or ischemic ulceration).
  • The subject has had a major amputation of the leg or any other amputation that limits walking ability.
  • The subject has diabetes mellitus type 1 or poorly controlled diabetes mellitus type 2 (hemoglobin A1c (HbA1c) > 10).
  • The subject has had a transient ischemic attack (TIA) or deep vein thrombosis in the last 3 months.
  • The subject has had a stroke within the last 6 months.
  • The subject has participated in an angiogenic gene therapy study, unless known to be given placebo.
  • The subject has any of the following laboratory parameters at Screening 1:

    • Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin >3 times the upper limit of normal (ULN)
    • Serum creatinine >2.5 mg/dL
    • Hemoglobin (Hb) <10 g/dL
    • White blood cell (WBC) count <3.0 x 103/µL; or > 15 x 103/µL
    • Platelet count <100 x 103/µL
  • The subject walks less than 1 minute at 2 miles per hour (mph), 0% grade as determined during the Screening 1 treadmill familiarization.
  • The subject has clinically significant electrocardiogram (ECG) abnormalities at rest or changes during exercise or post-exercise at Screening 2 or Day 0.
  • The subject has any history or clinical evidence of congestive heart failure (CHF), with which the clinician-investigator concurs.
  • The subject has uncontrolled hypertension (resting blood pressure (BP) > 180/100 mmHg) or uncontrolled arrhythmic disorders at Screening 1.
  • History of coronary or peripheral revascularization within 6 months prior to Screening 1.
  • The subject plans to undergo coronary or peripheral revascularization during the course of the study.
  • The subject is currently taking L-carnitine or medication for claudication (including pentoxifylline or cilostazol). In this situation, the subject would become eligible for Screening 1 after a 6 week washout of the medication.
  • Subjects currently taking or those who anticipate taking ketoconazole, itraconazole, or erythromycin. The subject would become eligible for Screening 1 immediately after completion of therapy or discontinuation of the drug(s).
  • The subject has a known, active malignancy that requires active anti-neoplastic therapy. (stable basal cell skin cancer allowed. Cancer being treated soley with hormonal therapy is allowed.)
  • The subject has a severe co-morbidity with an expected survival of less than 2 years.
  • The subject's Peak Walking Time (PWT) is limited by symptoms other than claudication (e.g., shortness of breath (SOB), fatigue, angina, arthritis, etc.). If, in the opinion of the investigator, the subject were to improve their Peak Walking Time (PWT) from study therapy to the extent that his or her walking would then be limited by a symptom other than claudication, the subject should not be enrolled.
  • The subject has a history of alcohol or other substance abuse within 6 months of Screening 1.
  • The subject has an inability to tolerate oral medication administration.
  • The subject has a known or suspected allergy to the study medication(s) or class of study medication(s) (cilostazol or L-carnitine) to be administered.
  • The subject has initiated an exercise training program within 3 months of Screening 1, has the inability to maintain his or her current level of physical activity throughout the study, or the subject plans on enrolling in an exercise training program during the study.
  • The subject plans to change his/her smoking status during the planned duration of this study (subjects will be advised that stopping smoking is best for his/her health).
  • The subject is currently pregnant or breastfeeding.
  • The subject has received an investigational drug or biological agent within 30 days prior to Screening 1.
  • The subject is currently participating in or plans to enroll in another clinical trial during this study.
  • The subject has any other clinically significant medical or psychiatric condition that in the opinion of the Investigator could impact the subject's ability to successfully complete this trial.
  • In the Investigator's opinion, the subject experienced any Adverse Events (AEs) during the tolerance phase of the Screening period that present a potential ongoing safety concern.
Both
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00822172
CPC-08-01
No
Colorado Prevention Center
Colorado Prevention Center
Otsuka Pharmaceutical Co., Ltd.
Study Chair: Neil Goldenberg, MD, PhD University of Colorado Heather Sciences Center
Colorado Prevention Center
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP